FDMT

4d Molecular Therapeutics, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000

$11.90Close $685.5MMarket cap $7.19 – $16.7652-week range Nov 9, 2026Next report

Highlights

Cautions

Trend not confirmed 6 of 8 conditions · under the 50-day, over 25% off the high
Far from its high 29% below its 52-week high
Distribution down-day volume 1.6× up-day volume over 50 sessions
Results soon Nov 9, 2026, in 8 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 13, 2026

Off 12-month high 29%

1wk 10.2% price change

1mo 16.8% price change

12-month return 5% market up 11% · its own down 7%

F-score — — Not assessed

Altman Z 4.97 Low risk

P/E — price / earnings

PEG — P/E / EPS growth

P/B 1.4× price / book

Earnings yield 25.5% EBIT / enterprise value

Cheaper than 31% of the market · expensive

Revenue growth 230195% year on year

EPS growth — latest quarter

Sales growth 25107% latest quarter · +3442 pts

ROE 28% return on equity

Free cash margin 129% -$109.6M FCF

D/E 0.00 long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Piotroski tests

Repair signals

Revenue reaccelerating (-100% then +230195%)

Trade setup

ATR% 8.1% $0.97 a day · 2×ATR $9.97

RS 78 / 99 vs the universe

Trend 6 / 8 under the 50-day, over 25% off the high

Relative volume 0.7× vs 50-day average

Up/down volume 0.62 50 sessions

Implied move — no option chain · report Nov 9, 2026

Trend template · 6 of 8

Price above the 50-day average: fails
Within 25% of the 52-week high: fails

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged

Shareholders diluted The share count rose 25.8% over the year, from 46m to 58m shares. Each existing share owns a smaller fraction of the company than it did a year ago.

Last reported Aug 13, 2026

Results reaction Aug 13, 2026+2% vs market2 sessions after results

Financials

6 fiscal years · from filings

Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $85.2M +230195% on FY2024

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$140.1M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$109.6M

Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology

Net -164%
Free cash -129%

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology $60.2M net cash

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 57.61m +115.9% since FY2020

	FY2020Dec 31, 2020	FY2021Dec 31, 2021	FY2022Dec 31, 2022	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Revenue	$13.4M	$18.0M	$3.1M	$20.7M	$37,000	$85.2M
Operating income	-$56.7M	-$71.3M	-$110.0M	-$112.9M	-$187.8M	-$159.5M
Net income	-$56.7M	-$71.3M	-$107.5M	-$100.8M	-$160.9M	-$140.1M
Net margin	-424%	-395%	-3435%	-487%	-434778%	-164%
Earnings per share	—	-$2.57	-$3.32	-$2.58	-$2.98	-$2.42
Free cash flow	-$51.9M	-$78.2M	-$98.2M	-$78.6M	-$138.4M	-$109.6M
Free cash margin	-388%	-434%	-3139%	-379%	-373976%	-129%
Cash	$276.7M	$153.0M	$52.4M	$249.1M	$149.3M	$60.2M
Long-term debt	—	—	—	—	—	$0
Shareholders' equity	$256.4M	$319.1M	$231.3M	$307.8M	$510.6M	$505.7M
Shares outstanding	26.68m	32.22m	32.63m	43.08m	45.79m	57.61m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 13, 2026	Quarterly ↗	Jun 30, 2026	44d
May 7, 2026	Quarterly ↗	Mar 31, 2026	37d
Mar 18, 2026	Annual ↗	Dec 31, 2025	77d
Nov 10, 2025	Quarterly ↗	Sep 30, 2025	41d
Aug 11, 2025	Quarterly ↗	Jun 30, 2025	42d
May 8, 2025	Quarterly ↗	Mar 31, 2025	38d
Feb 28, 2025	Annual ↗	Dec 31, 2024	59d
Nov 13, 2024	Quarterly ↗	Sep 30, 2024	44d
Aug 8, 2024	Quarterly ↗	Jun 30, 2024	39d
May 9, 2024	Quarterly ↗	Mar 31, 2024	39d
Feb 29, 2024	Annual ↗	Dec 31, 2023	60d
Nov 9, 2023	Quarterly ↗	Sep 30, 2023	40d

Current reports

Filed	Disclosed
Sep 28, 2026	Other events ↗
Aug 13, 2026	Results ↗
Jul 20, 2026	Other events ↗
Jun 29, 2026	Material agreement · New obligation ↗
Jun 22, 2026	Shareholder vote ↗
May 7, 2026	Results ↗
Mar 30, 2026	Director or officer change ↗
Mar 18, 2026	Results ↗
Jan 26, 2026	Unregistered share sale ↗
Jan 7, 2026	Results · Director or officer change ↗
Dec 10, 2025	Other events ↗
Nov 17, 2025	Director or officer change ↗